Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Fintel reports that on March 10, 2025, Lake Street downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and ...

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the ...

India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted ...

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.